Literature DB >> 9015257

Morphologic changes in age-related maculopathy.

M Kliffen1, T L van der Schaft, C M Mooy, P T de Jong.   

Abstract

Age-related maculopathy (ARM) is a degenerative disorder of the central part of the retina with a rising prevalence in patients 50 years of age and older, and comprises different histopathological changes. The morphologic changes in ARM are described and illustrated with light-microscopical, electron microscopical, and fundus pictures. Furthermore, the most important biochemical data are given. The most prominent aging changes in early stages of ARM are drusen and basal laminar deposit (BLD), both extracellular deposits, that are assumed to be important in the development of ARM. Drusen accumulate within Bruch's membrane, whereas BLD is present between Bruch's membrane and the retinal pigment epithelium. Although the histopathologic characteristics of the deposits are well documented, the chemical composition has only been partly resolved. Biochemical analysis of these deposits is necessary to determine the source of the deposits and to find possible ways to avoid or treat them. The late stages of ARM, geographic atrophy, and neovascular (disciform) degeneration, are called age-related macular degeneration (AMD), and result in severe and irreversible visual impairment. Since there is still no adequate therapy for the majority of people disabled by AMD, and because of the aging population resulting in even more patients with this disease, it is necessary to intensify the research on ARM in order to prevent AMD or find a therapy for it.

Entities:  

Mesh:

Year:  1997        PMID: 9015257     DOI: 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  26 in total

Review 1.  Why study rod cell death in retinal degenerations and how?

Authors:  C E Remé; C Grimm; F Hafezi; H P Iseli; A Wenzel
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

2.  The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit.

Authors:  M Kliffen; E Lutgens; M J Daemen; E D de Muinck; C M Mooy; P T de Jong
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 3.  Genetic factors of age-related macular degeneration.

Authors:  Jingsheng Tuo; Christine M Bojanowski; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

4.  The Project MACULA Retinal Pigment Epithelium Grading System for Histology and Optical Coherence Tomography in Age-Related Macular Degeneration.

Authors:  Emma C Zanzottera; Jeffrey D Messinger; Thomas Ach; R Theodore Smith; K Bailey Freund; Christine A Curcio
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

5.  NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration.

Authors:  Alexander G Marneros
Journal:  Cell Rep       Date:  2013-09-05       Impact factor: 9.423

Review 6.  Glycobiology of ocular angiogenesis.

Authors:  Anna I Markowska; Zhiyi Cao; Noorjahan Panjwani
Journal:  Glycobiology       Date:  2014-08-08       Impact factor: 4.313

7.  Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration.

Authors:  N L Mata; J Weng; G H Travis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  A CTRP5 gene S163R mutation knock-in mouse model for late-onset retinal degeneration.

Authors:  Venkata R M Chavali; Naheed W Khan; Catherine A Cukras; Dirk-Uwe Bartsch; Monica M Jablonski; Radha Ayyagari
Journal:  Hum Mol Genet       Date:  2011-02-24       Impact factor: 6.150

Review 9.  Minireview: Fibronectin in retinal disease.

Authors:  Charles G Miller; Greg Budoff; Jonathan L Prenner; Jean E Schwarzbauer
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-20

10.  Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels.

Authors:  Zsolt Ablonczy; Mohammad Dahrouj; Alexander G Marneros
Journal:  FASEB J       Date:  2014-02-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.